AU2343388A - Treatment of lipoprotein disorders associated with cholesterol metabolism - Google Patents

Treatment of lipoprotein disorders associated with cholesterol metabolism

Info

Publication number
AU2343388A
AU2343388A AU23433/88A AU2343388A AU2343388A AU 2343388 A AU2343388 A AU 2343388A AU 23433/88 A AU23433/88 A AU 23433/88A AU 2343388 A AU2343388 A AU 2343388A AU 2343388 A AU2343388 A AU 2343388A
Authority
AU
Australia
Prior art keywords
treatment
disorders associated
cholesterol metabolism
cholesterol
lipoprotein disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU23433/88A
Other versions
AU611204B2 (en
Inventor
Manfred Berger
Daniele Spielmann
Helmut Traitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2343388A publication Critical patent/AU2343388A/en
Application granted granted Critical
Publication of AU611204B2 publication Critical patent/AU611204B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Blackcurrant seed oil has been found particularly effective in the treatment of lipoprotein anomalies linked to cholesterol metabolism. Its administration makes it possible to increase significantly the cholesterol in high-density lipoproteins while reducing cholesterol in low-density lipoproteins, and thus reduces the cardiovascular risk.
AU23433/88A 1987-10-16 1988-10-05 Treatment of lipoprotein disorders associated with cholesterol metabolism Ceased AU611204B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4069/87 1987-10-16
CH4069/87A CH673223A5 (en) 1987-10-16 1987-10-16

Publications (2)

Publication Number Publication Date
AU2343388A true AU2343388A (en) 1989-04-20
AU611204B2 AU611204B2 (en) 1991-06-06

Family

ID=4269238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23433/88A Ceased AU611204B2 (en) 1987-10-16 1988-10-05 Treatment of lipoprotein disorders associated with cholesterol metabolism

Country Status (10)

Country Link
EP (1) EP0311866B1 (en)
JP (1) JPH075471B2 (en)
AT (1) ATE72987T1 (en)
AU (1) AU611204B2 (en)
CA (1) CA1314229C (en)
CH (1) CH673223A5 (en)
DE (1) DE3868827D1 (en)
ES (1) ES2036650T3 (en)
GR (1) GR3003990T3 (en)
IE (1) IE61682B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622500B2 (en) * 1988-12-23 1992-04-09 Societe Des Produits Nestle S.A. Blackcurrant lipid for inhibitation of cell adhesion

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6325289U (en) * 1986-07-31 1988-02-19
JP2917037B2 (en) * 1990-01-09 1999-07-12 株式会社アドバンス ACAT inhibitor
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
JP2006014730A (en) * 2004-05-31 2006-01-19 Toyo Shinyaku:Kk Food product

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2834227A1 (en) * 1978-08-04 1980-02-28 Merck Patent Gmbh HYPO-BETA -LIPOPROTEINAEMIC DIETETIC, METHOD FOR THE PRODUCTION AND USE THEREOF
EP0092076B1 (en) * 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Lipid composition for oral, enteral or parenteral feeding
JPS61118318A (en) * 1984-11-12 1986-06-05 Pola Chem Ind Inc Composition having improving action on serum lipid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622500B2 (en) * 1988-12-23 1992-04-09 Societe Des Produits Nestle S.A. Blackcurrant lipid for inhibitation of cell adhesion

Also Published As

Publication number Publication date
EP0311866B1 (en) 1992-03-04
JPH01132530A (en) 1989-05-25
CA1314229C (en) 1993-03-09
ATE72987T1 (en) 1992-03-15
GR3003990T3 (en) 1993-03-16
DE3868827D1 (en) 1992-04-09
IE61682B1 (en) 1994-11-16
JPH075471B2 (en) 1995-01-25
IE882989L (en) 1989-04-16
AU611204B2 (en) 1991-06-06
EP0311866A1 (en) 1989-04-19
CH673223A5 (en) 1990-02-28
ES2036650T3 (en) 1993-06-01

Similar Documents

Publication Publication Date Title
GR3019179T3 (en) Flupirtine in combination with antiparkinsonica against muscle bracing
PT2145627E (en) Use of uridine in combination with choline for the treatment of mood and emotional disorders
MX263227B (en) Methods and pharmaceutical compositions useful for treating neurological disorders
BG101993A (en) Dialkylethers containing end carboxylic or tetrazole groups
HK1012213A1 (en) Dietary compositions and methods using bile salt-activated lipase
EP0283513A4 (en) Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases.
JPS5791915A (en) Novel lipid composition useful for dietetics, resuscitation and treatment
PT1056357E (en) HIGHLY HEALTHY NUTRITION COMPOSITION
WO1999011252A3 (en) N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain
GR3006073T3 (en)
DE69523654T2 (en) Use of ascorbyl gamma linolenate and ascorbyl dihomo gamma linolenate for the treatment of asthma, cancer, cardiovascular and inflammatory diseases
AU569920B2 (en) Administration of gangliosides by inhalation
AU2343388A (en) Treatment of lipoprotein disorders associated with cholesterol metabolism
AU567186B2 (en) Tar and linolenic acid topical preparation
AU3133889A (en) Method for the treatment of the extraphyramidal side effects associated with neuroleptic therapy
AU563273B2 (en) Composition containing an essential fatty acid and niacin and/or a bile salt binder
MX170573B (en) PROCEDURE FOR MAKING BEVERAGES CONTAINING ORANGE JUICE WITH A STABLE SHELF LIFE
FR2668039B1 (en) DIETETIC DRINK INTENDED TO SUPPORT EFFORT.
HUT47299A (en) Process for producing pharmaceutical influencing cerebral metabolism and neuronal transmission
AU1218092A (en) High stability oils
EP0293900A3 (en) Phenolic thioethers, sulfoxides, and disulfides as inhibitors of 5-lipoxygenase
ATE19855T1 (en) PHARMACEUTICAL AND DIETETIC COMPOSITION.
NZ298141A (en) Treating lipid metabolism disorder using TCF-II
IL89901A (en) Strobilurine derivative
Wahking Therapy with theological constructs and tactics.